澳门威斯人(0168-认证VIP网站)-Best APP Platform

2020 官网升级中！现在您访问官网的浏览器设备分辨率宽度低于1280px
请使用高分辨率宽度访问。

Scrllo Down

HOME NEWS

Company News Media Coverage

01-042023

BioRay Pharmaceutical Announces USD218 Million Strategic Financing Round

January 4, 2023 -- BioRay Pharmaceutical Co., Ltd., China’s leading autoimmune-focused biopharmaceutical firm, announced it has entered into definitive agreements for a strategic round of financing at a pre-money valuation of RMB13 billion (USD1.9 billi

07-202022

BioRay Announces First-Patient-In for Phase I Clinical study of BR105 in patients with advanced Malignant Tumors

BioRay will push forward with our research and development projects in the field of popular targets for tumor immunity and autoimmunity to benefit patients.

01-122022

BioRay announces IND approval for the Phase I self-developed Category 1 innovative drug BR 105 study

The approval of BR105 injection in clinical trials will further enrich BioRay's product pipeline.

01-072022

The New Drug Application of BioRay’s Zuberitamab Injection has been accepted by China's National Medical Products Administration

BioRay announced that NMPA) had accepted the New Drug Application for the self-developed Category 1 innovative drug Zuberitamab (R&D Code: HS006, Trade name: Anruixi) for the first-line treatment of CD20 Positive Non-Hodgkin lymphoma (Acceptance No. CXSS2

12-022021

BioRay Announces First-Patient-In for Phase II Clinical study of Zuberitamab in Patients with Primary immunologic thrombocytopenic purpura

BioRay announced that the first patient with Primary immunologic thrombocytopenic purpura (ITP) had been dosed in the Phase II Clinical trial of self-developed Zuberitamab (development code: HS006).

09-282021

BioRay Infliximab for Injection (Anbaite®) received marketing authorization

BioRay announced that the National Medical Products Administration (NMPA) of China approved the application for marketing of its own human-mouse chimeric monoclonal antibody targeting human tumor necrosis factor-α (TNF-α), Infliximab for Injection (Anbait

TO TOP